Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
The primary objective is to document the safety of tecemotide (L-BLP25) phase III formulation
in non-small cell lung cancer (NSCLC) subjects with unresectable Stage III disease. This
population includes Stage IIIA NSCLC subjects, a population not studied in former clinical
studies with this vaccine. The secondary objective is to document the survival of subjects
treated.